After the first-step study in a small number of young children to test different doses, Pfizer is ready to enroll about 4,500 young volunteers at more than 90 sites in the U.S., Finland, Poland, and Spain.
The vaccine made by Pfizer and its German partner BioNTech already is authorized for emergency use in anyone 12 and older in the U.S. and European Union.
Today begins the Phase 2/3 part of our continuous study of the Pfizer – @BioNTech #COVID19 vaccine in healthy children. This is the next step allowing us to gather data to understand the safety and immunogenicity of the vaccine in this group aged 5–11 years.— Pfizer Inc. (@pfizer) June 8, 2021
Enrollment of 5- to 11-year-olds began this week. Those youngsters will receive two vaccine doses of 10 micrograms each – a third of the teen and adult dose – or dummy shots. Enrollment of children as young as 6 months will start in a few weeks using an even lower dose, 3 micrograms per shot.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)